Patents Assigned to PRILENIA NEUROTHERAPEUTICS LTD.
-
Publication number: 20220062255Abstract: This application provides a method of treating a subject afflicted with a neurodegenerative eye disease comprising administering to the subject an amount of pridopidine effective to treat the subject, pharmaceutical composition and uses and applications thereof.Type: ApplicationFiled: October 28, 2021Publication date: March 3, 2022Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michal Geva, Hermann Kurt Russ, Ralph Laufer, Aric Orbach
-
Patent number: 11234973Abstract: The invention provides a method of treating a subject afflicted with fragile X syndrome (FXS) or a FXS related disorder, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to treat the subject.Type: GrantFiled: July 17, 2019Date of Patent: February 1, 2022Assignees: PRILENIA NEUROTHERAPEUTICS LTD., NATIONAL UNIVERSITY OF SINGAPORE, Agency for Science, Technology and ResearchInventors: Michael Hayden, Mahmoud Abdulhossein Pouladi
-
Patent number: 11207308Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in articular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.Type: GrantFiled: November 28, 2018Date of Patent: December 28, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Ross Nicholas Waters, Eva Susanna Holm Waters
-
Patent number: 11207310Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.Type: GrantFiled: August 24, 2017Date of Patent: December 28, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor Grachev
-
Patent number: 11141412Abstract: This invention provides an isolated compound having the structure: or a salt thereof, processes for making the same and to compositions comprising pridopidine with these compounds.Type: GrantFiled: August 8, 2019Date of Patent: October 12, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Malle Schmidt, Malle Pari, Marit Laos, Ants Maasalu, Kalle Kaljuste
-
Publication number: 20210308115Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 20, 2021Publication date: October 7, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Merav Bassan, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Publication number: 20210275512Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine or pharmaceutically acceptable salt thereof effective to treat the subject.Type: ApplicationFiled: May 10, 2021Publication date: September 9, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michal GEVA, Aric Orbach, Michael Hayden
-
Patent number: 11090297Abstract: A method of treating a human patient afflicted with Huntington's disease, comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine, its analog or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 12, 2019Date of Patent: August 17, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Merav Bassan, Esther Lukasiewicz Hagai, Eli Eyal, Anna Kristina Sveinsdotter Teige Wickenberg
-
Publication number: 20210220342Abstract: The subject invention provides a method for treating a subject afflicted with a disease, disorder, or condition associated with mitochondrial dysfunction or ER stress, comprising administering to the subject a composition comprising pridopidine or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: February 23, 2021Publication date: July 22, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michael HAYDEN, Michal GEVA, Ana Cristina CARVALHO REGO
-
Patent number: 11000519Abstract: The invention provides a method of treating a subject afflicted with a drug-induced movement disorder including levodopa-induced dyskinesia comprising periodically administering to the subject in need thereof an amount of pridopidine effective to treat the subject. The invention further provides a method of treating a subject at risk of developing a drug-induced movement disorder, including levodopa-induced dyskinesia. The invention also provides pharmaceutical compositions suitable for carrying out these methods and packages containing such pharmaceutical compositions.Type: GrantFiled: June 11, 2019Date of Patent: May 11, 2021Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michal Geva, Aric Orbach, Michael Hayden
-
Publication number: 20210106572Abstract: The subject invention provides a method for treating a subject afflicted with Rett syndrome comprising administering to the subject an effective amount of pridopidine so as to thereby treat the subject.Type: ApplicationFiled: November 19, 2020Publication date: April 15, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN
-
Publication number: 20210093622Abstract: The invention provides a method of reducing anxiety and/or depression in a subject comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine effective to reduce anxiety and/or depression in a subject.Type: ApplicationFiled: October 20, 2020Publication date: April 1, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michael HAYDEN, Mahmoud Abdulhossein POULADI
-
Publication number: 20210052560Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.Type: ApplicationFiled: September 13, 2020Publication date: February 25, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michael Hayden, Michal Geva
-
Publication number: 20210030734Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine.Type: ApplicationFiled: October 21, 2020Publication date: February 4, 2021Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michal GEVA, Michael Hayden
-
Patent number: 10799492Abstract: The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. In other aspects the invention relates to pharmaceutical compositions comprising a deuterated analog of Pridopidine of the invention, and to therapeutic applications of these analogs.Type: GrantFiled: September 17, 2018Date of Patent: October 13, 2020Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventor: Clas Sonesson
-
Publication number: 20200188305Abstract: The subject invention provides a solid unit dosage form comprising pridopidine or pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form has a volume and wherein the ratio of the amount of pridopidine to the volume of the dosage form is 135-600 mg/ml.Type: ApplicationFiled: February 27, 2020Publication date: June 18, 2020Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Danit LICHT, Ioana LOVINGER
-
Publication number: 20200179355Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine as monotherapy or together with riluzole, edaravone, combination of dextromethorphan/quinidine, sodium phenylbutyrate (PB), tauroursodeoxycholic acid or combination of sodium phenylbutyrate (PB)/tauroursodeoxycholic acid (i.e. AMX0035) as combination or add-on therapy.Type: ApplicationFiled: February 13, 2020Publication date: June 11, 2020Applicant: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Michal GEVA, Ralph LAUFER, Michael HAYDEN, Neta ZACH
-
Patent number: 10603311Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.Type: GrantFiled: February 24, 2016Date of Patent: March 31, 2020Assignees: PRILENIA NEUROTHERAPEUTICS LTD., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
-
Publication number: 20200093813Abstract: This invention provides a method of improving cognitive function in a subject comprising periodically administering to the subject an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to improve a cognitive function in the subject. The invention also provides a method of treating a subject afflicted with Alzheimer's disease, comprising periodically administering to the subject a pharmaceutical composition comprising an amount of pridopidine or a pharmaceutically acceptable salt thereof effective to treat the subject.Type: ApplicationFiled: October 3, 2019Publication date: March 26, 2020Applicants: PRILENIA NEUROTHERAPEUTICS LTD., THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEMInventors: Michal Geva, Ilya Bezprozvanny, Merav Bassan, Michael Hayden
-
Publication number: 20200000785Abstract: This invention relates to novel pharmaceutical compositions comprising a therapeutically effective combination of a dopaminergic stabilizer known as Pridopidine, and an inhibitor of the vesicular monoamine transporter type 2 (VMAT) known as Tetrabenazine. The pharmaceutical compositions for use according to the invention are contemplated particularly useful for improving the symptomatic therapeutic effects, and for reducing the adverse effects, of Tetrabenazine in the treatment of movement disorders, and in particular movement disorders associated with Huntington's disease, Gilles de la Tourette's syndrome, or tardive dyskinesia.Type: ApplicationFiled: November 28, 2018Publication date: January 2, 2020Applicant: Prilenia Neurotherapeutics Ltd.Inventors: Ross Nicholas Waters, Eva Susanna Holm Waters